利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

224 条记录 (耗时 0.052 秒)

    Tetracyclic bicyclolides
    21.
    发明授权
    Tetracyclic bicyclolides 失效
    四环双环体

    公开(公告)号：US07312201B2

    公开(公告)日：2007-12-25

    申请号：US11302525

    申请日：2005-12-13

    申请人： Datong Tang ,  Yonghua Gai ,  Ying Sun ,  Yat Sun Or ,  Zhe Wang

    发明人： Datong Tang ,  Yonghua Gai ,  Ying Sun ,  Yat Sun Or ,  Zhe Wang

    IPC分类号： A61K31/70 ,  C07H17/08

    CPC分类号： C07H17/08

    摘要： The present invention discloses compounds of formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The invention further includes process by which to make the compounds of the present invention.

    摘要翻译： 本发明公开了式I化合物或其药学上可接受的盐，酯或前药：其表现出抗菌性质。 本发明还涉及包含上述化合物的药物组合物，用于给予需要抗生素治疗的受试者。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的细菌感染的方法。 本发明还包括制备本发明化合物的方法。

    Macrocyclic oximyl hepatitis C protease inhibitors
    22.
    发明申请
    Macrocyclic oximyl hepatitis C protease inhibitors 审中-公开
    大环肟基丙型肝炎蛋白酶抑制剂

    公开(公告)号：US20070281884A1

    公开(公告)日：2007-12-06

    申请号：US11502740

    申请日：2006-08-11

    申请人： Ying Sun ,  Deqiang Niu ,  Guoyou Xu ,  Yat Sun Or ,  Zhe Wang

    发明人： Ying Sun ,  Deqiang Niu ,  Guoyou Xu ,  Yat Sun Or ,  Zhe Wang

    IPC分类号： A61K38/12 ,  A61K31/395 ,  C07K5/12

    CPC分类号： A61K38/212 ,  A61K38/12 ,  A61K38/215 ,  C07K5/0804 ,  A61K2300/00

    摘要： The present invention discloses compounds of formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

    摘要翻译： 本发明公开了式I化合物或其药学上可接受的盐，酯或前药：其抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶的活性。 因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。 本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。

    Oximyl macrocyclic derivatives
    23.
    发明授权
    Oximyl macrocyclic derivatives 有权
    甲氧基大环衍生物

    公开(公告)号：US08268777B2

    公开(公告)日：2012-09-18

    申请号：US12327453

    申请日：2008-12-03

    申请人： Ying Sun ,  Deqiang Niu ,  Guoyou Xu ,  Yat Sun Or ,  Zhe Wang

    发明人： Ying Sun ,  Deqiang Niu ,  Guoyou Xu ,  Yat Sun Or ,  Zhe Wang

    IPC分类号： A61K38/00

    CPC分类号： C07D245/04

    摘要： The present invention relates to compounds of Formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising a compound of the present invention.

    摘要翻译： 本发明涉及式I化合物或其药学上可接受的盐，酯或前体药物：其抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶的活性。 因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。 本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。

    Macrocylic oximyl hepatitis C protease inhibitors
    24.
    发明授权
    Macrocylic oximyl hepatitis C protease inhibitors 失效
    大蓖麻丙型肝炎蛋白酶抑制剂

    公开(公告)号：US08268776B2

    公开(公告)日：2012-09-18

    申请号：US12016643

    申请日：2008-01-18

    申请人： Ying Sun ,  Deqiang Niu ,  Guoyou Xu ,  Yat Sun Or ,  Zhe Wang

    发明人： Ying Sun ,  Deqiang Niu ,  Guoyou Xu ,  Yat Sun Or ,  Zhe Wang

    IPC分类号： A61K38/00

    CPC分类号： C07K5/0804 ,  C07K5/0812 ,  C07K7/06

    摘要： The present invention discloses compounds of formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

    摘要翻译： 本发明公开了式I化合物或其药学上可接受的盐，酯或前药：其抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶的活性。 因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。 本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。

    OXIMYL MACROCYCLIC DERIVATIVES
    26.
    发明申请
    OXIMYL MACROCYCLIC DERIVATIVES 有权
    OXIMYL MACROCYCLIC衍生物

    公开(公告)号：US20090191153A1

    公开(公告)日：2009-07-30

    申请号：US12327453

    申请日：2008-12-03

    申请人： Ying Sun ,  Deqiang Niu ,  Guoyou Xu ,  Yat Sun Or ,  Zhe Wang

    发明人： Ying Sun ,  Deqiang Niu ,  Guoyou Xu ,  Yat Sun Or ,  Zhe Wang

    IPC分类号： A61K31/407 ,  C07D487/04 ,  A61K31/4439 ,  A61K31/501 ,  A61K31/497 ,  A61K31/427 ,  A61K31/506 ,  A61K31/496 ,  A61K31/5377 ,  A61K31/54 ,  A61K31/55 ,  A61P31/12 ,  A61K38/21 ,  A61K31/708

    CPC分类号： C07D245/04

    摘要： The present invention relates to compounds of Formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising a compound of the present invention.

    摘要翻译： 本发明涉及式I化合物或其药学上可接受的盐，酯或前体药物：其抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶的活性。 因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。 本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。

    Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
    28.
    发明授权
    Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors 有权
    喹喔啉基大环丙型肝炎丝氨酸蛋白酶抑制剂

    公开(公告)号：US08236807B2

    公开(公告)日：2012-08-07

    申请号：US12505725

    申请日：2009-07-20

    申请人： Suanne Nakajima ,  Zhenwei Miao ,  Ying Sun ,  Datong Tang ,  Guoyou Xu ,  Brian Porter ,  Yat Sun Or ,  Zhe Wang

    发明人： Suanne Nakajima ,  Zhenwei Miao ,  Ying Sun ,  Datong Tang ,  Guoyou Xu ,  Brian Porter ,  Yat Sun Or ,  Zhe Wang

    IPC分类号： C07D401/12 ,  C07D409/14 ,  A61K31/38 ,  A61K31/395 ,  A61P31/12

    CPC分类号： C07K5/0802 ,  A61K38/212 ,  A61K38/215 ,  C07D487/04 ,  C07K5/0804 ,  A61K2300/00

    摘要： The present invention relates to compounds of Formula I or II, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

    摘要翻译： 本发明涉及抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶活性的式I或II化合物或其药学上可接受的盐，酯或前药。 因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。 本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。

    QUINOXALINYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS
    29.
    发明申请
    QUINOXALINYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS 有权
    喹诺酮类大环内酯类抗生素C丝氨酸蛋白酶抑制剂

    公开(公告)号：US20080152622A1

    公开(公告)日：2008-06-26

    申请号：US12043421

    申请日：2008-03-06

    申请人： Suanne Nakajima ,  Zhenwei Miao ,  Ying Sun ,  Datong Tang ,  Guoyou Xu ,  Brian Porter ,  Yat Sun Or ,  Zhe Wang

    发明人： Suanne Nakajima ,  Zhenwei Miao ,  Ying Sun ,  Datong Tang ,  Guoyou Xu ,  Brian Porter ,  Yat Sun Or ,  Zhe Wang

    IPC分类号： A61K38/12 ,  A61K38/21 ,  C07K5/12 ,  A61P31/12

    CPC分类号： C07K5/0802 ,  A61K38/212 ,  A61K38/215 ,  C07D487/04 ,  C07K5/0804 ,  A61K2300/00

    摘要： The present invention relates to compounds of Formula I or II, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

    摘要翻译： 本发明涉及抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶的活性的式I或II化合物或其药学上可接受的盐，酯或前药。 因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。 本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。